Sorrento Therapeutics Inc SRNE

NAS: SRNE | ISIN: US83587F2020   1/05/2025
0,001 USD (0,00%)
(0,00%)   1/05/2025

21 februari 2023 · Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case · Persbericht

16 februari 2023 · Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions · Persbericht

2 juni 2022 · Caris Life Sciences, Prostate Cancer Clinical Trial Consortium and Sorrento Therapeutics Announce Collaboration to Advance Precision Medicine Development Using Comprehensive Genomic Profiling · Persbericht

20 januari 2022 · Sorrento Therapeutics Announces Covishield (Sti-9167), A Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron And Omicron (+R346K) Variants Of Sars-Cov-2 · Persbericht

18 maart 2021 · Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate · Persbericht

17 maart 2021 · Dr. Henry Ji to Participate in the CEO Roundtable during WuXi Healthcare Forum 2021 on March 17, 2021 · Persbericht

13 maart 2021 · SORRENTO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sorrento Therapeutics, Inc. - SRNE · Persbericht

8 maart 2021 · Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer · Persbericht

5 maart 2021 · Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference · Persbericht

2 maart 2021 · Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients · Persbericht

8 februari 2021 · Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic · Persbericht

31 januari 2021 · Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells · Persbericht

27 januari 2021 · Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients · Persbericht

19 januari 2021 · Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein · Persbericht

19 januari 2021 · Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021 · Persbericht

10 januari 2021 · Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference · Persbericht

Mijn selecties